A judge has dismissed a legal challenge aimed at forcing Elsevier to retract a long-criticized study that concluded the antidepressant Paxil was safe and effective for teens.
The 2001 paper, published in the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP), has faced scrutiny for more than 20 years by critics who say the study has led to unwarranted and potentially harmful prescribing of the drug to youth. As we reported last October, the journal placed an expression of concern on the paper shortly after a lawsuit was filed by attorney George W. Murgatroyd III against the journal’s owner, the American Academy of Child and Adolescent Psychiatry (AACAP), and Elsevier, which publishes the title.
In his complaint, filed in the Superior Court of the District of Columbia, Murgatroyd claimed the journal is violating the D.C. Consumer Protection Procedures Act (CPPA) by continuing to “publish, distribute, and sell a fraudulent scientific article that contains material facts” that mislead the public and endanger adolescent mental health and safety. AACAP and Elsevier are profiting from the article by charging readers to buy access to the paper, according to the complaint.
Continue reading Judge tosses lawsuit over controversial Paxil ‘Study 329’
